I noticed I have 27 boardmarks, why are you bm me...... I am a newb!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I hope they are pushing for Regional accreditation as that would make them much more desirable.
Additional volume at .09 range.
.08 x .09 and .09 getting some love.
Back at .08 x .09 IRSB
Tomorrow they have a call.
Aspen Group, Inc. to Announce Fiscal 2016 2nd Quarter Results on Wednesday, December 2nd
Nov 17, 2015
OTC Disclosure & News Service
-
NEW YORK, Nov. 17, 2015 (GLOBE NEWSWIRE) -- Aspen Group, Inc. (OTCQB:ASPU), parent of Aspen University, a nationally accredited online postsecondary education company, will host a conference call to discuss its fiscal year 2016 second quarter (ending October 31, 2015) financial results and business outlook on Wednesday, December 2, 2015, at 5:00 p.m. (ET). Aspen will issue a press release reporting results after the market closes on Wednesday, December 2.
The conference call can be accessed by dialing toll-free (844) 452-6823 (U.S.) or (731) 256-5216 (international). Subsequent to the call, a transcript of the audiocast will be available from the Company’s website at ir.aspen.edu.
About Aspen Group, Inc. (OTCQB:ASPU)
Aspen Group, Inc. is an online postsecondary education company. Aspen University’s mission is to offer any motivated college-worthy student the opportunity to receive a high-quality, responsibly priced distance-learning education for the purpose of achieving sustainable economic and social benefits for themselves and their families. Aspen is dedicated to providing the highest quality education experiences taught by top-tier faculty – 60 percent of our adjunct faculty hold doctoral degrees. To learn more about Aspen University, visit www.aspen.edu.
Media Contact:
Aspen Group, Inc.
Michael Mathews, CEO
914-906-9159
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 20, 2015, Aspen Group, Inc. (the “Company”) amended the Company’s 2012 Equity Incentive Plan (the “Plan”) to increase the number of authorized shares under the Plan by 4 million shares to a total of 20.3 million shares.
In addition, on November 20, 2015, as compensation for their services on a special committee of the Board of Directors, the Company granted 250,000 five-year stock options (exercisable at $0.165 per share) to each of C. James Jensen, Andrew Kaplan and Rick Solomon. The options vest in three equal annual increments with the first vesting date being one year from the grant date, subject to continued service as a director on each applicable vesting date.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
.08 x .09. Slowly and surely we are seeing accumulation occurring. Per the previous PR there are items in work.
Slow and Steady .07 x .09
.173 x .185
patience works with me.
Iris BioTechnologies Inc. Reports on Legal Proceedings Involving Heller Ehrman LLP
1:18 pm ET November 25, 2015 (Market Wire) Print
On November 20, 2015, the Ninth Circuit Court of Appeals affirmed the lower court decision denying Iris's motion to file a malpractice claim against its former legal counsel Heller Ehrman LLP. Heller Ehrman was a reputable, one-hundred-plus-years-old law firm with more than 600 attorneys. Heller Ehrman was Iris BioTechnologies' patent counsel from February 1999 to September 2011.
The basis for Iris's malpractice claim was Heller's failure to forward key communications from the United States Patent and Trademark Office (USPTO).
On December 10, 2007, a letter from Heller to Iris stated, "We will forward all correspondence and faxes which we may receive concerning your applications from the (USPTO)." Iris's patent attorney, James A. Fox, also told Iris that there was nothing for Iris to do until further communications from the USPTO. Heller never changed its guidance, which Iris followed as it waited for Heller to forward any USPTO communications.
On March 21, 2008, the USPTO sent Heller an important letter pertaining to Iris patent application. Heller, as the Bankruptcy Court found, did not forward the letter to Iris. As a result of Heller's failure to reply to the USPTO, the patent application became abandoned.
In October 2008, the USPTO sent a second letter notifying Heller that Iris's patent application had become abandoned because of a non-reply to their March 21, 2008 letter. Again, as the Bankruptcy Court found, Heller failed to forward the letter to Iris.
In December 2008, Heller, unbeknownst to Iris, filed for bankruptcy protection. The Bankruptcy court then set a deadline of April 27, 2009 for claims against Heller to be filed. Again, Heller did not notify Iris that there was a claim-filing deadline.
In August 2011, Iris's patent attorney in Canada, who was prosecuting a related patent application, discovered Heller's malpractice and informed Iris. On the same day, Iris CEO Simon Chin contacted Iris's patent attorney at Heller, James A. Fox. He then filed a petition to disengage Iris from Heller and revived the patent application. The patent application was later granted. Iris submitted claims to Heller in April 2012, and Heller denied the claims on June 11, 2012.
Iris CEO Simon Chin, commenting on the Ninth Circuit's ruling, stated, "While we are disappointed with the Ninth Circuit's ruling, this matter is not over. Iris has been and will continue to pursue all alternative legal avenues to vindicate its rights."
Iris maintains Heller Ehrman's failure to notify of key developments from the USPTO constituted legal malpractice. Heller's malpractice prevented Iris from qualifying to be listed on the NASDAQ in 2008 and prevented Iris from being able to raise the capital, at a fair market valuation, for its product launches. The company was also denied the opportunity to stop competitors from infringing on its patents. In addition, Heller Ehrman's malpractice significantly delayed the collection of licensing fees and seriously damaged the value of the company's IP.
Despite all the damage Heller caused Iris, the company continues to develop its technologies, products, and services. In April 2014, Iris was granted a key patent, which Iris believes could be worth hundreds of millions of dollars when fully applied. In the same month, Iris was recognized with the IAIR Award for the Best Company for Leadership in Personalized Medicine in North America. On June 18, 2014, Iris's common stock (OTCQB: IRSB) reached $4.50 per share.
Iris is happy to report that the European Union will be issuing Iris a patent on December 9, 2015 relating to the company's Artificial Intelligence System for Genetic Analysis. This is a significant addition to Iris's six US patents and a portfolio of patents worldwide.
Throughout the past year, Iris has been investing in people, equipment, and software to conduct leading edge research and development on miniaturizing and multiplexing our nano-biochips as well as deep diving on understanding biology, medicine, and new imaging systems. Iris will continue to do so.
Iris plans to launch multiple products in 2016 both in the US and abroad. Iris will soon hold focus meetings in various cities regarding its products and services as well as a multitude of options for rapid collaboration and expansion.
About Iris BioTechnologies Inc.
Iris BioTechnologies Inc. (OTCQB: IRSB) is a life sciences company focused on providing accurate, affordable precision healthcare, which is the future of medicine. Iris offers the best approach to the treatment of cancer and other diseases through actionable integration of molecular profiling in the clinical decision-making process. In the treatment of cancer, we can achieve precision analysis of chemotherapy effectiveness as well as risk of recurrence. We accomplish this by incorporating DNA, RNA and protein analysis with a patient's medical records, family medical history, life style and environmental exposures. Iris enables personal precision healthcare by matching patient to targeted treatments, and in some cases, including therapies in clinical trials.
The Iris Nano-Biochip(TM) product pipeline includes: CancerChip(TM), PrenatalChip(TM), Integrated Blood Test, IVF applications, NeuroChip(TM) (Alzheimer's and Parkinson diseases), MetabolicChip(TM) (Diabetes), CardioChip(TM), and Chips for veterinary, agricultural, environmental, and other applications. The Iris BioWindows(TM) artificial intelligence system provides big data and analysis for clinical applications, drug development, and stem cell research.
For more information on Iris BioTechnologies Inc., please visit Iris on Facebook (https://www.facebook.com/irisbiotech), Twitter (https://twitter.com/irisbiotech), and the Iris corporate website (www.irisbiotech.com).
Iris BioTechnologies Inc.
Simon Chin
408-806-7149
President and CEO
simonchin@irisbiotech.com
SOURCE: Iris BioTechnologies Inc.
mailto:simonchin@irisbiotech.com
.0451 x .07
.1675 x .184 has the gap filled?
.161 x .1625
Just in case you did not see an update
Iris BioTechnologies Inc. Reports on Legal Proceedings Involving Heller Ehrman LLP
1:18 pm ET November 25, 2015 (Market Wire) Print
On November 20, 2015, the Ninth Circuit Court of Appeals affirmed the lower court decision denying Iris's motion to file a malpractice claim against its former legal counsel Heller Ehrman LLP. Heller Ehrman was a reputable, one-hundred-plus-years-old law firm with more than 600 attorneys. Heller Ehrman was Iris BioTechnologies' patent counsel from February 1999 to September 2011.
The basis for Iris's malpractice claim was Heller's failure to forward key communications from the United States Patent and Trademark Office (USPTO).
On December 10, 2007, a letter from Heller to Iris stated, "We will forward all correspondence and faxes which we may receive concerning your applications from the (USPTO)." Iris's patent attorney, James A. Fox, also told Iris that there was nothing for Iris to do until further communications from the USPTO. Heller never changed its guidance, which Iris followed as it waited for Heller to forward any USPTO communications.
On March 21, 2008, the USPTO sent Heller an important letter pertaining to Iris patent application. Heller, as the Bankruptcy Court found, did not forward the letter to Iris. As a result of Heller's failure to reply to the USPTO, the patent application became abandoned.
In October 2008, the USPTO sent a second letter notifying Heller that Iris's patent application had become abandoned because of a non-reply to their March 21, 2008 letter. Again, as the Bankruptcy Court found, Heller failed to forward the letter to Iris.
In December 2008, Heller, unbeknownst to Iris, filed for bankruptcy protection. The Bankruptcy court then set a deadline of April 27, 2009 for claims against Heller to be filed. Again, Heller did not notify Iris that there was a claim-filing deadline.
In August 2011, Iris's patent attorney in Canada, who was prosecuting a related patent application, discovered Heller's malpractice and informed Iris. On the same day, Iris CEO Simon Chin contacted Iris's patent attorney at Heller, James A. Fox. He then filed a petition to disengage Iris from Heller and revived the patent application. The patent application was later granted. Iris submitted claims to Heller in April 2012, and Heller denied the claims on June 11, 2012.
Iris CEO Simon Chin, commenting on the Ninth Circuit's ruling, stated, "While we are disappointed with the Ninth Circuit's ruling, this matter is not over. Iris has been and will continue to pursue all alternative legal avenues to vindicate its rights."
Iris maintains Heller Ehrman's failure to notify of key developments from the USPTO constituted legal malpractice. Heller's malpractice prevented Iris from qualifying to be listed on the NASDAQ in 2008 and prevented Iris from being able to raise the capital, at a fair market valuation, for its product launches. The company was also denied the opportunity to stop competitors from infringing on its patents. In addition, Heller Ehrman's malpractice significantly delayed the collection of licensing fees and seriously damaged the value of the company's IP.
Despite all the damage Heller caused Iris, the company continues to develop its technologies, products, and services. In April 2014, Iris was granted a key patent, which Iris believes could be worth hundreds of millions of dollars when fully applied. In the same month, Iris was recognized with the IAIR Award for the Best Company for Leadership in Personalized Medicine in North America. On June 18, 2014, Iris's common stock (OTCQB: IRSB) reached $4.50 per share.
Iris is happy to report that the European Union will be issuing Iris a patent on December 9, 2015 relating to the company's Artificial Intelligence System for Genetic Analysis. This is a significant addition to Iris's six US patents and a portfolio of patents worldwide.
Throughout the past year, Iris has been investing in people, equipment, and software to conduct leading edge research and development on miniaturizing and multiplexing our nano-biochips as well as deep diving on understanding biology, medicine, and new imaging systems. Iris will continue to do so.
Iris plans to launch multiple products in 2016 both in the US and abroad. Iris will soon hold focus meetings in various cities regarding its products and services as well as a multitude of options for rapid collaboration and expansion.
About Iris BioTechnologies Inc.
Iris BioTechnologies Inc. (OTCQB: IRSB) is a life sciences company focused on providing accurate, affordable precision healthcare, which is the future of medicine. Iris offers the best approach to the treatment of cancer and other diseases through actionable integration of molecular profiling in the clinical decision-making process. In the treatment of cancer, we can achieve precision analysis of chemotherapy effectiveness as well as risk of recurrence. We accomplish this by incorporating DNA, RNA and protein analysis with a patient's medical records, family medical history, life style and environmental exposures. Iris enables personal precision healthcare by matching patient to targeted treatments, and in some cases, including therapies in clinical trials.
The Iris Nano-Biochip(TM) product pipeline includes: CancerChip(TM), PrenatalChip(TM), Integrated Blood Test, IVF applications, NeuroChip(TM) (Alzheimer's and Parkinson diseases), MetabolicChip(TM) (Diabetes), CardioChip(TM), and Chips for veterinary, agricultural, environmental, and other applications. The Iris BioWindows(TM) artificial intelligence system provides big data and analysis for clinical applications, drug development, and stem cell research.
For more information on Iris BioTechnologies Inc., please visit Iris on Facebook (https://www.facebook.com/irisbiotech), Twitter (https://twitter.com/irisbiotech), and the Iris corporate website (www.irisbiotech.com).
Iris BioTechnologies Inc.
Simon Chin
408-806-7149
President and CEO
simonchin@irisbiotech.com
SOURCE: Iris BioTechnologies Inc.
mailto:simonchin@irisbiotech.com
Iris BioTechnologies Inc. Reports on Legal Proceedings Involving Heller Ehrman LLP
1:18 pm ET November 25, 2015 (Market Wire) Print
On November 20, 2015, the Ninth Circuit Court of Appeals affirmed the lower court decision denying Iris's motion to file a malpractice claim against its former legal counsel Heller Ehrman LLP. Heller Ehrman was a reputable, one-hundred-plus-years-old law firm with more than 600 attorneys. Heller Ehrman was Iris BioTechnologies' patent counsel from February 1999 to September 2011.
The basis for Iris's malpractice claim was Heller's failure to forward key communications from the United States Patent and Trademark Office (USPTO).
On December 10, 2007, a letter from Heller to Iris stated, "We will forward all correspondence and faxes which we may receive concerning your applications from the (USPTO)." Iris's patent attorney, James A. Fox, also told Iris that there was nothing for Iris to do until further communications from the USPTO. Heller never changed its guidance, which Iris followed as it waited for Heller to forward any USPTO communications.
On March 21, 2008, the USPTO sent Heller an important letter pertaining to Iris patent application. Heller, as the Bankruptcy Court found, did not forward the letter to Iris. As a result of Heller's failure to reply to the USPTO, the patent application became abandoned.
In October 2008, the USPTO sent a second letter notifying Heller that Iris's patent application had become abandoned because of a non-reply to their March 21, 2008 letter. Again, as the Bankruptcy Court found, Heller failed to forward the letter to Iris.
In December 2008, Heller, unbeknownst to Iris, filed for bankruptcy protection. The Bankruptcy court then set a deadline of April 27, 2009 for claims against Heller to be filed. Again, Heller did not notify Iris that there was a claim-filing deadline.
In August 2011, Iris's patent attorney in Canada, who was prosecuting a related patent application, discovered Heller's malpractice and informed Iris. On the same day, Iris CEO Simon Chin contacted Iris's patent attorney at Heller, James A. Fox. He then filed a petition to disengage Iris from Heller and revived the patent application. The patent application was later granted. Iris submitted claims to Heller in April 2012, and Heller denied the claims on June 11, 2012.
Iris CEO Simon Chin, commenting on the Ninth Circuit's ruling, stated, "While we are disappointed with the Ninth Circuit's ruling, this matter is not over. Iris has been and will continue to pursue all alternative legal avenues to vindicate its rights."
Iris maintains Heller Ehrman's failure to notify of key developments from the USPTO constituted legal malpractice. Heller's malpractice prevented Iris from qualifying to be listed on the NASDAQ in 2008 and prevented Iris from being able to raise the capital, at a fair market valuation, for its product launches. The company was also denied the opportunity to stop competitors from infringing on its patents. In addition, Heller Ehrman's malpractice significantly delayed the collection of licensing fees and seriously damaged the value of the company's IP.
Despite all the damage Heller caused Iris, the company continues to develop its technologies, products, and services. In April 2014, Iris was granted a key patent, which Iris believes could be worth hundreds of millions of dollars when fully applied. In the same month, Iris was recognized with the IAIR Award for the Best Company for Leadership in Personalized Medicine in North America. On June 18, 2014, Iris's common stock (OTCQB: IRSB) reached $4.50 per share.
Iris is happy to report that the European Union will be issuing Iris a patent on December 9, 2015 relating to the company's Artificial Intelligence System for Genetic Analysis. This is a significant addition to Iris's six US patents and a portfolio of patents worldwide.
Throughout the past year, Iris has been investing in people, equipment, and software to conduct leading edge research and development on miniaturizing and multiplexing our nano-biochips as well as deep diving on understanding biology, medicine, and new imaging systems. Iris will continue to do so.
Iris plans to launch multiple products in 2016 both in the US and abroad. Iris will soon hold focus meetings in various cities regarding its products and services as well as a multitude of options for rapid collaboration and expansion.
About Iris BioTechnologies Inc.
Iris BioTechnologies Inc. (OTCQB: IRSB) is a life sciences company focused on providing accurate, affordable precision healthcare, which is the future of medicine. Iris offers the best approach to the treatment of cancer and other diseases through actionable integration of molecular profiling in the clinical decision-making process. In the treatment of cancer, we can achieve precision analysis of chemotherapy effectiveness as well as risk of recurrence. We accomplish this by incorporating DNA, RNA and protein analysis with a patient's medical records, family medical history, life style and environmental exposures. Iris enables personal precision healthcare by matching patient to targeted treatments, and in some cases, including therapies in clinical trials.
The Iris Nano-Biochip(TM) product pipeline includes: CancerChip(TM), PrenatalChip(TM), Integrated Blood Test, IVF applications, NeuroChip(TM) (Alzheimer's and Parkinson diseases), MetabolicChip(TM) (Diabetes), CardioChip(TM), and Chips for veterinary, agricultural, environmental, and other applications. The Iris BioWindows(TM) artificial intelligence system provides big data and analysis for clinical applications, drug development, and stem cell research.
For more information on Iris BioTechnologies Inc., please visit Iris on Facebook (https://www.facebook.com/irisbiotech), Twitter (https://twitter.com/irisbiotech), and the Iris corporate website (www.irisbiotech.com).
Iris BioTechnologies Inc.
Simon Chin
408-806-7149
President and CEO
simonchin@irisbiotech.com
SOURCE: Iris BioTechnologies Inc.
mailto:simonchin@irisbiotech.com
34,000 x .05 + 20,400 x .06 + 30,400 x .065 + 85,000 x .07 = $10,850
wtf happened here????
if anyone watches L2 on this its almost hilarious.
You will see the bid slowly creeping up .1675 now. You will see the ask have 5K shares (hiding the true amount sometimes).
Hi Stirling it seems you are correct in regards to November 12th, however the Nov 18th purchase according to the following he also did buy shares from .05-07 as well. Is this not correct?
http://www.otcmarkets.com/stock/IRSB/insider-transactions
.16666 x .18
Joe you still keeping track of ASPU?
http://seekingalpha.com/article/1786752-aspen-group-soaring-revenues-and-declining-losses
ASPU Bid is starting to creep up.
.051 x .055
Not concerned as of right now, we have some time and the conference call is on December.
.055 x .06
Seems like folks do not have any patience these days.
.165 x .17
.06 x .069. Some selling occurring and shares are being absorbed by people on the bid.
.162 x .17
.063 x .069
.063 x .07
I am a idiot I was talking about the 10K worth of shares of form 4 however,
The Form 4 filed for 2,659,574 at .047 = $124999.978 Acquisition (Non Open Market)
.08 x .095 watching to see how .095 range does.
Interesting note looking at the one year chart. The most volume this stock has received has been in the past month. Does anyone know the reason for the decline, as there seems to be lots of room for upward growth (obviously the opposite can be true, however with the CEO purchasing shares between .05-.07 I wonder if there is a base line that has been created).
Looking at the chart for about 2 months it has been trending up and having higher highs and higher lows. I would only hope we continue the trend, and as the company approaches profitability. To get more eyes and interest.
.08 x .09 IR_SB keeping an eye.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11013075
CEO buys 10K worth shares.
Are you still watching this, noted after CEO form 4 purchased $10,000 worth shares.
34,000 x .05 + 20,400 x .06 + 30,400 x .065 + 85,000 x .07 = $10,850... not a small purchase in my mind. Doing some digging
Roy are all the transactions from CEO buying acquired as in given shares or purchased via private/public transaction?
.1601 x .17